INmune Bio receives ~$4.6M in R&D rebates from Australia and UK, extends cash runway

Inmune Bio, Inc.

Received ~$4.2M R&D cash rebate from Australia on July 30, 2026, plus ~$0.4M from UK in June 2026.
Combined ~$4.6M in non-dilutive rebates exceeded net cash used in Q2 operating activities (after adjusting for UK rebate).
Strengthens balance sheet and extends cash runway without issuing additional equity.
Rebates support advancement of CORDStrom toward regulatory filings (MAA UK MHRA 2026, EU EMA 2027, US BLA).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.